Top

Published in:

01-04-2012 | Original Article

Heterogeneity in clonal nature in the smoldering subtype of adult T-cell leukemia: continuity from carrier status to smoldering ATL

Authors: Shimeru Kamihira, Masako Iwanaga, Yuko Doi, Daisuke Sasaki, Sayaka Mori, Kazuto Tsurda, Kazuhiro Nagai, Naoki Uno, Hiroo Hasegawa, Katsunori Yanagihara, Yoshitomo Morinaga, Kunihiro Tsukasaki, Hiroaki Taniguchi

Published in: International Journal of Hematology | Issue 4/2012

Abstract

To better understand indeterminate HTLV-1 carriers and smoldering (SM) subtype of adult T-cell leukemia (ATL), HTLV-1 proviral integrated status, proviral load (PVL) and ATL-related biomarkers were examined in 57 smoldering cases, including unusual carriers with a percentage of ATL-like cells. We found that according to Southern blot hybridization analytic features, 28 patients with SM ATL could be divided into 3 groups consisting of 16 (57.4%) patients with a monoclonal band, 6 (21.4%) with oligoclonal bands and the remaining 6 with smears. Although no clinical differences were observed among the 3 SM subtypes, HTLV-1-infected CD4 T-cell counts increased in order of poly-, oligo- and monoclonal subtypes. This trend began in the carrier stage and also was observed in PVL, CD25 and CCR4, indicating that a clone consisting of leukemic phenotypic cells was continuously growing. Moreover, the antigen modulation rates of CD26 and CD7 and the increasing rate of CD25 and CCR4 cells were closely correlated to growing clonal size, indicating that these markers had the possibility to predict a monoclonal band. In particular, CD26 or the ratio of CD26/CD25 had a validity differential for leukemic nature and predictive detection of clonal band. Conclusively, the present study shows that smoldering ATL is heterogeneous in the leukemogenic process, and the behavior of CD26 plays a central role in the evolution from early occult to overt smoldering ATL.

Poiesz BJ, Ruscetti FW, Gazdar AF, Robbert Gallo C. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of patients with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA. 1980;77(12):7415–9.PubMedCrossRef

Matsuoka M, Jeang KT. Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat Rev Cancer. 2007;7(4):270–80.PubMedCrossRef

Yoshida M. Discovery of HTLV-1, the first human retrovirus, its unique regulatory mechanisms, and insights into pathogenesis. Oncogene. 2005;24(39):5931–7.PubMedCrossRef

Tanaka G, Okayama A, Watanabe T, Aizawa S, Stuver S, Mueller N, Hsieh CC, Tsubouchi H. The clonal expansion of human T lymphotropic virus type 1-infected T cells: a comparison between seroconverters and long-term carriers. J Infect Dis. 2005;91(7):1140–7.CrossRef

Kamihira S, Sugahara K, Tsuruda K, Minami S, Uemura A, Akamatsu N, Nagai H, Murata K, Hasegawa H, Hirakata Y, Takasaki Y, Tsukasaki K, Yamada Y. Proviral status of HTLV-1 integrated into the host genomic DNA of adult T-cell leukemia cells. Clin Lab Haematol. 2005;27(4):235–41.PubMedCrossRef

Sugahara K, Yamada Y. Southern blot hybridization analysis for lymphoid neoplasms. Rinsho Byori. 2000;48(8):702–7.PubMed

Kamihira S, Sohda H, Atogami S, Fukushima T, Toriya K, Miyazaki Y, Ikeda S, Yamada Y, Tomonaga M. Unusual morphological features of adult T-cell leukemia cells with aberrant immunophenotype. Leuk Lymphoma. 1993;12(1–2):123–30.PubMedCrossRef

Maeda T, Yamada Y, Moriuchi R, Sugahara K, Tsuruda K, Joh T, Atogami S, Tsukasaki K, Tomonaga M, Kamihira S. Fas gene mutation in the progression of adult T cell leukemia. J Exp Med. 1999;189(7):1063–71.PubMedCrossRef

Tsuji T, Sugahara K, Tsuruda K, Uemura A, Harasawa H, Hasegawa H, Hamaguchi Y, Tomonaga M, Yamada Y, Kamihira S. Clinical and oncologic implications in epigenetic down-regulation of CD26/dipeptidyl peptidase IV in adult T-cell leukemia cells. Int J Hematol. 2004;80(3):254–60.PubMedCrossRef

10.

Sasaki D, Doi Y, Hasegawa H, Yanagihara K, Tsukasaki K, Iwanaga M, Yamada Y, Watanabe T, Kamihira S. High human T cell leukemia virus type-1 (HTLV-1) provirus load in patients with HTLV-1 carriers complicated with HTLV-1-unrelated disorders. Virol J. 2010;7:81.PubMedCrossRef

11.

Kamihira S, Dateki N, Sugahara K, Yamada Y, Tomonaga M, Maeda T, Tahara M. Real-time polymerase chain reaction for quantification of HTLV-1 proviral load: application for analyzing aberrant integration of the proviral DNA in adult T-cell leukemia. Int J Hematol. 2000;72(1):79–84.PubMed

12.

Kamihira S, Dateki N, Sugahara K, Hayashi T, Harasawa H, Minami S, Hirakata Y, Yamada Y. Significance of HTLV-1 proviral load quantification by real-time PCR as a surrogate marker for HTLV-1-infected cell count. Clin Lab Haematol. 2003;25(2):111–7.PubMedCrossRef

13.

Uemura A, Sugahara K, Nagai H, Murata K, Hasegawa H, Hirakata Y, Tsukasaki K, Yamada Y, Kamihira S. An ATL cell line with an IgH pseudo-rearranged band pattern by Southern blotting: a pitfall of genetic diagnosis. Lab Hematol. 2005;11(1):8–13.PubMedCrossRef

14.

Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984–87). Br J Haematol. 1991;79(3):428–37.PubMedCrossRef

15.

Gillet NA, Malani N, Melamed A, Gormley N, Carter R, Bentley D, Berry C, Bushman FD, Taylor GP, Bangham CR. The host genomic environment of the provirus determines the abundance of HTLV-1-infected T-cell clones. Blood. 2011;117(11):3113–22.PubMedCrossRef

16.

Ariyama Y, Mori T, Shinomiya T, Sakabe T, Fukuda Y, Kanamaru A, Yamada Y, Isobe M, Seto M, Nakamura Y, Inazawa J. Chromosomal imbalances in adult T-cell leukemia revealed by comparative genomic hybridization: gains at 14q32 and 2p16-22 in cell lines. J Hum Genet. 1999;44(6):357–63.PubMedCrossRef

17.

Tian Y, Kobayashi S, Ohno N, Isobe M, Tsuda M, Zaike Y, Watanabe N, Tani K, Tojo A, Uchimaru K. Leukemic T cells are specifically enriched in a unique CD3 (dim) CD7 (low) subpopulation of CD4(+) T cells in acute-type adult T-cell leukemia. Cancer Sci. 2011;102(3):569–77.PubMedCrossRef

18.

Kelemen K, Guitart J, Kuzel TM, Goolsby CL, Peterson LC. The usefulness of CD26 in flow cytometric analysis of peripheral blood in Sézary syndrome. Am J Clin Pathol. 2008;129(1):146–56.PubMedCrossRef

19.

Sato T, Yamochi T, Yamochi T, Aytac U, Ohnuma K, McKee KS, Morimoto C, Dang NH. CD26 regulates p38 mitogen-activated protein kinase-dependent phosphorylation of integrin beta1, adhesion to extracellular matrix, and tumorigenicity of T-anaplastic large cell lymphoma Karpas 299. Cancer Res. 2005;65(15):6950–6.PubMedCrossRef

20.

Narducci MG, Scala E, Bresin A, Caprini E, Picchio MC, Remotti D, Ragone G, Nasorri F, Frontani M, Arcelli D, Volinia S, Lombardo GA, Baliva G, Napolitano M, Russo G. Skin homing of Sézary cells involves SDF-1-CXCR4 signaling and down-regulation of CD26/dipeptidylpeptidase IV. Blood. 2006;107(3):1108–15.PubMedCrossRef

21.

Abe M, Uchihshi K, Tsuruda K, Kamihira S. Foxp3 expression on normal and leukemic CD4+CD25+ T-cells implicated in HTLC-1 is inconsistent with Treg cells. Europ J Haematol. 2008;81:209–17.CrossRef

Title: Heterogeneity in clonal nature in the smoldering subtype of adult T-cell leukemia: continuity from carrier status to smoldering ATL
Authors: Shimeru Kamihira
Masako Iwanaga
Yuko Doi
Daisuke Sasaki
Sayaka Mori
Kazuto Tsurda
Kazuhiro Nagai
Naoki Uno
Hiroo Hasegawa
Katsunori Yanagihara
Yoshitomo Morinaga
Kunihiro Tsukasaki
Hiroaki Taniguchi
Publication date: 01-04-2012
Publisher: Springer Japan
Published in: International Journal of Hematology / Issue 4/2012
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-012-1020-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2012

Guest editorial: current understanding of thrombosis and hemostasis—from bench to bedside

Ex vivo expansion of umbilical cord blood: where are we?

Elucidating disparities across racial and ethnic groups in multiple myeloma patients

Prenatal screening for β-thalassemia major reveals new and rare mutations in the Pakistani population

Polyphosphate: a link between platelets, coagulation and inflammation

High frequency of inherited variants in the MEFV gene in patients with hematologic neoplasms: a genetic susceptibility?

Keynote webinar | Spotlight on antibody–drug conjugates in cancer